UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000031495
Receipt No. R000035097
Scientific Title Prospective investigation of efficacy for blood culture of a new antiseptic Olanexidine Gluconate 1.5%.
Date of disclosure of the study information 2018/02/28
Last modified on 2019/03/29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Prospective investigation of efficacy for blood culture of a new antiseptic Olanexidine Gluconate 1.5%.
Acronym Prospective investigation of efficacy for blood culture of a new antiseptic Olanexidine Gluconate 1.5%.
Scientific Title Prospective investigation of efficacy for blood culture of a new antiseptic Olanexidine Gluconate 1.5%.
Scientific Title:Acronym Prospective investigation of efficacy for blood culture of a new antiseptic Olanexidine Gluconate 1.5%.
Region
Japan

Condition
Condition Case of suspected blood stream infection with blood culture.
Classification by specialty
Medicine in general Surgery in general Emergency medicine
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 This study was designed to measure the efficacy and the safety of a new antiseptic Olanexidine gluconate in these patients with blood stream infection.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Primary outcome is the ratio of contamination.
Key secondary outcomes Secondary outcome is determined to assess the rate of any adverse effect such as vital sign, subjective and objective symptom, erythema or irritation of the skin.

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Diagnosis
Type of intervention
Medicine
Interventions/Control_1 Apply 1.5% Olamexidine gluconate twice, then dry it before applying blood culture.
Blood cultures are taken 2 sets and the result is judged as contamination with the result.
The skin site exposed to 1.5% Olamexidine gluconate are inspected any adverse effect such as vital sign, subjective and objective symptom, erythema or irritation of the skin.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria (1)Case in which blood culture was carried out on suspicion of bloodstream infection over 38 degrees or clinically carried out in Kodo hospital during daytime on weekdays.
(2)Patients who understand the contents of the examination, and can observe it
(3)Agreement from patients or subsutituted person
Key exclusion criteria (1)Patients already receiving antibiotic treatment
(2)Patients who had an allergy to a study drug or gluconic acid chlorhexidine
(3)Patients who judged inappropriate cases
Target sample size 100

Research contact person
Name of lead principal investigator
1st name Takahiro
Middle name
Last name Yamamoto
Organization Koto hospital
Division name Division of emergency
Zip code 1360072
Address 6-8-5 oojima koto-ku tokyo 136-0072
TEL 03-3685-2166
Email gakkai@gogomotty.com

Public contact
Name of contact person
1st name Takahiro
Middle name
Last name Yamamoto
Organization Koto hospital
Division name Division of emergency
Zip code 1360072
Address 6-8-5 oojima koto-ku tokyo 136-0072
TEL 03-3685-2166
Homepage URL
Email gakkai@gogomotty.com

Sponsor
Institute Koto hospital
Institute
Department

Funding Source
Organization none
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Koto hospital
Address 6-8-5 oojima koto-ku tokyo 136-0072
Tel 03-3685-2166
Email miurakunihisa@yahoo.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 02 Month 28 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2017 Year 07 Month 01 Day
Date of IRB
2017 Year 07 Month 01 Day
Anticipated trial start date
2017 Year 07 Month 01 Day
Last follow-up date
2018 Year 12 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2018 Year 02 Month 27 Day
Last modified on
2019 Year 03 Month 29 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035097

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.